Servier Acquires Day One Biopharmaceuticals for $2.5 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 hours ago
0mins
Should l Buy DAWN?
Source: PRnewswire
- Acquisition Overview: Servier has entered into a definitive agreement to acquire Day One Biopharmaceuticals for $21.50 per share in cash, totaling approximately $2.5 billion, with the transaction expected to close in Q2 2026, reinforcing Servier's position in oncology targeted therapies.
- Strategic Alignment: This acquisition aligns with Servier's 2030 ambition to develop innovative treatments for patients with high unmet medical needs, enhancing its oncology pipeline with programs ranging from early-stage to phase 3.
- Combining Expertise: The merger of Day One's scientific expertise with Servier's established global capabilities advances a shared commitment to delivering innovative solutions for patients worldwide, particularly in the rare cancer treatment space.
- Patient-First Philosophy: Day One CEO Jeremy Bender emphasized that Servier's dedication to the rare disease community aligns with Day One's mission, ensuring the continuation of a patient-first mindset that drives their commitment to the communities they serve.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DAWN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DAWN
Wall Street analysts forecast DAWN stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 12.780
Low
16.00
Averages
22.29
High
29.00
Current: 12.780
Low
16.00
Averages
22.29
High
29.00
About DAWN
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. It partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. OJEMDA is used for the treatment of patients over six months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Its pipeline product candidates include DAY301 and Emi-Le (emiltatug ledadotin). DAY301 is a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. Emi-Le (emiltatug ledadotin) is a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Day One Biopharmaceuticals Acquired for $2.5 Billion, Leading to Surge in Stock Prices.
- Acquisition Announcement: Day One Biopharmaceuticals will be acquired by French drugmaker Servier in an all-cash deal.
- Share Price Surge: Following the announcement, shares of Day One Biopharmaceuticals increased significantly, reaching $21.50 each.
See More
DAY ONE BIOPHARMACEUTICALS STOCK JUMPS 65.4% FOLLOWING $2.5 BILLION ACQUISITION OFFER FROM SERVIER
Stock Performance: Day One Biopharmaceuticals shares increased by 65.4%.
Acquisition Announcement: The rise in shares follows the announcement of a $2.5 billion acquisition offer for the company.
See More
Ademi LLP Investigates Day One for Possible Legal Violations
- Shareholder Rights Investigation: Ademi LLP is investigating Day One (NASDAQ:DAWN) for potential breaches of fiduciary duty in its transaction with Servier, which may impact shareholder rights.
- Transaction Details Revealed: In this deal, Day One shareholders will receive $21.50 per share in cash, representing a total equity value of approximately $2.5 billion, indicating a substantial return on investment.
- Competitive Transaction Restrictions: The transaction agreement imposes significant penalties for accepting competing bids, which could undermine the best interests of shareholders by limiting their options.
- Board Conduct Review: We are examining whether the Day One board has fulfilled its fiduciary duties to all shareholders, ensuring that their decisions align with the overall interests of the shareholders.
See More
U.S. Stocks Decline Amid Weak Retail Sales Data
- Market Performance: U.S. stocks broadly declined during trading, with the S&P 500 falling approximately 1%, the Dow down 0.99% to 47,479.25, and the NASDAQ dropping 0.86% to 22,554.26, indicating market concerns over economic outlook.
- Retail Sales Data: U.S. retail sales fell by 0.2% month-over-month in January, missing market estimates of a 0.3% decline, reflecting weak consumer spending that could negatively impact economic growth.
- Sector Movements: While the overall market declined, energy stocks rose by 0.5%, contrasting with a 2.1% drop in financial stocks, indicating sector divergence that may influence investor asset allocation strategies.
- International Market Dynamics: European shares fell broadly, with the eurozone's STOXX 600 down 1.04%, while Asian markets mostly gained, suggesting varying performances across regions that could affect global investor confidence.
See More
Bank Stocks Decline While Fertilizer Stocks Rally Amid Supply Concerns
- Bank Stocks Decline: All 101 stocks in the State Street SPDR S&P Bank ETF (KBE) fell on Friday as the spread between the 2- and 10-year Treasury yields widened, with Western Alliance Bancorp down nearly 12%, indicating rising future inflation expectations that could compress banks' net interest margins and increase credit risk.
- Fertilizer Stocks Rally: Fertilizer stocks surged again due to tight supplies from the Iran conflict, with CF Industries climbing 5% to a new 52-week high and a week-to-date gain of about 17%, reflecting strong market expectations for fertilizer demand amid geopolitical tensions.
- Airline Stocks Under Pressure: United Airlines shares tumbled nearly 4% after CEO Scott Kirby warned that rising fuel prices would have a
See More
Marvell Technology Surges After Strong Q4 Earnings Report
- Strong Earnings Report: Marvell Technology reported fourth-quarter revenue of $2.22 billion, slightly exceeding the market consensus of $2.21 billion, indicating robust performance in the semiconductor sector and reinforcing its market position.
- Earnings Beat Expectations: Adjusted earnings came in at $0.80 per share, surpassing the expected $0.79, demonstrating significant progress in cost control and operational efficiency, which enhances investor confidence.
- Significant Stock Surge: Following the positive earnings report, Marvell's stock price jumped 18.4% to $89.56 during Friday's trading session, reflecting optimistic market expectations regarding the company's future growth potential.
- Positive Market Reaction: Despite a broader market decline with the Dow Jones index falling around 500 points, Marvell's strong earnings attracted investor attention, showcasing its resilience in an uncertain market environment.
See More
Day One Biopharmaceuticals Acquired for $2.5 Billion, Leading to Surge in Stock Prices.
- Acquisition Announcement: Day One Biopharmaceuticals will be acquired by French drugmaker Servier in an all-cash deal.
- Share Price Surge: Following the announcement, shares of Day One Biopharmaceuticals increased significantly, reaching $21.50 each.
See More
DAY ONE BIOPHARMACEUTICALS STOCK JUMPS 65.4% FOLLOWING $2.5 BILLION ACQUISITION OFFER FROM SERVIER
Stock Performance: Day One Biopharmaceuticals shares increased by 65.4%.
Acquisition Announcement: The rise in shares follows the announcement of a $2.5 billion acquisition offer for the company.
See More
Ademi LLP Investigates Day One for Possible Legal Violations
- Shareholder Rights Investigation: Ademi LLP is investigating Day One (NASDAQ:DAWN) for potential breaches of fiduciary duty in its transaction with Servier, which may impact shareholder rights.
- Transaction Details Revealed: In this deal, Day One shareholders will receive $21.50 per share in cash, representing a total equity value of approximately $2.5 billion, indicating a substantial return on investment.
- Competitive Transaction Restrictions: The transaction agreement imposes significant penalties for accepting competing bids, which could undermine the best interests of shareholders by limiting their options.
- Board Conduct Review: We are examining whether the Day One board has fulfilled its fiduciary duties to all shareholders, ensuring that their decisions align with the overall interests of the shareholders.
See More
U.S. Stocks Decline Amid Weak Retail Sales Data
- Market Performance: U.S. stocks broadly declined during trading, with the S&P 500 falling approximately 1%, the Dow down 0.99% to 47,479.25, and the NASDAQ dropping 0.86% to 22,554.26, indicating market concerns over economic outlook.
- Retail Sales Data: U.S. retail sales fell by 0.2% month-over-month in January, missing market estimates of a 0.3% decline, reflecting weak consumer spending that could negatively impact economic growth.
- Sector Movements: While the overall market declined, energy stocks rose by 0.5%, contrasting with a 2.1% drop in financial stocks, indicating sector divergence that may influence investor asset allocation strategies.
- International Market Dynamics: European shares fell broadly, with the eurozone's STOXX 600 down 1.04%, while Asian markets mostly gained, suggesting varying performances across regions that could affect global investor confidence.
See More
Bank Stocks Decline While Fertilizer Stocks Rally Amid Supply Concerns
- Bank Stocks Decline: All 101 stocks in the State Street SPDR S&P Bank ETF (KBE) fell on Friday as the spread between the 2- and 10-year Treasury yields widened, with Western Alliance Bancorp down nearly 12%, indicating rising future inflation expectations that could compress banks' net interest margins and increase credit risk.
- Fertilizer Stocks Rally: Fertilizer stocks surged again due to tight supplies from the Iran conflict, with CF Industries climbing 5% to a new 52-week high and a week-to-date gain of about 17%, reflecting strong market expectations for fertilizer demand amid geopolitical tensions.
- Airline Stocks Under Pressure: United Airlines shares tumbled nearly 4% after CEO Scott Kirby warned that rising fuel prices would have a
See More
Marvell Technology Surges After Strong Q4 Earnings Report
- Strong Earnings Report: Marvell Technology reported fourth-quarter revenue of $2.22 billion, slightly exceeding the market consensus of $2.21 billion, indicating robust performance in the semiconductor sector and reinforcing its market position.
- Earnings Beat Expectations: Adjusted earnings came in at $0.80 per share, surpassing the expected $0.79, demonstrating significant progress in cost control and operational efficiency, which enhances investor confidence.
- Significant Stock Surge: Following the positive earnings report, Marvell's stock price jumped 18.4% to $89.56 during Friday's trading session, reflecting optimistic market expectations regarding the company's future growth potential.
- Positive Market Reaction: Despite a broader market decline with the Dow Jones index falling around 500 points, Marvell's strong earnings attracted investor attention, showcasing its resilience in an uncertain market environment.
See More
